Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2008) 16 P188


Virgen Macarena Hospital, Seville, Spain.


Objectives: To value the quality of life improvement and metabolic control in patients with DM1 in the 2 first years of treatment with insulin pump therapy.

Material and methods: We studied 33 DM1 patients, 16 men (48.5%) and 17 women (51.5%), with average age of 34.2±12.2 and 16.3±10.21 years of disease. Pump indication was hypoglycemia in 10 (30.3%), badly metabolic control in 14 (42.4%), pregnancy in 5 (15.2%) and glycemic inestability in 4 (12.1%). Following parameters pre-treatment were valued to the 3, 12 and 18 months: HbA1c, total insulin (IU/kg), BMI, glycemia average, hypoglycemias and number of controls/day. All filled the WHO questionnaire of treatment satisfaction previous to implantation of I.S.C.I., to 6 and 12 months.

Results:

PreBeginning6 m12 m18 m
HbA1c8.0±1.97.5±1.66.8±1.36.4±0.5*6.3±0.7
IU/kg0.76±0.30.56±0.30.57±0.20.65±0.30.45±0.1
BMI25.4±4.325.05±4.025.37±3.925.14±3.225.89±2.6
Glycemia157.2±32155.4±24.5151.7±50.1156.5±52.1151.4±12.3
Variability86.7±20.383.2±20.773.3±23.8*96.5±45.279.1±15.1
Hypoglycemias/month8.1±6.510.6±8.24.5±3.9*6.08±5.2*4.20±2.4
Controls/day1.76±0.83.59±1.94.14±1.63.2±1.23.46±0.5
*P<0.05; P<0.01.

Conclusions: A significant reduction of HbA1c was obtained in patients with insulin pump, specially during the first month. The HbA1c descended before treatment in relation to the educative program. The number of hypoglycemias decreased three months after the beginning. A greater satisfaction with I.S.C.I was observed at the 6 and 12 months.

Article tools

My recent searches

No recent searches.